Zilver PTX Post-Market Study in Japan

Conditions

Peripheral Arterial Disease (PAD)

Brief summary

Japanese post market clinical study of the Zilver PTX device.

Masayuki Sugimoto, Kimihiro Komori, Hiroyoshi Yokoi, Takao Ohki, Kimihiko Kichikawa et al. (11 authors)

Journal of Endovascular Therapy2020-10-2112 citations

10.1177/1526602820966708

Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent

Michael D. Dake, Fabrizio Fanelli, Aaron E. Lottes, Erin E. O’Leary, Heidi Reichert et al. (12 authors)

CardioVascular and Interventional Radiology2020-10-0614 citations

10.1007/s00270-020-02648-6

Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.

Kichikawa K, Ichihashi S, Yokoi H, Ohki T, Nakamura M, Komori K, Nanto S, O'Leary EE, Lottes AE, Snyder SA, Dake MD.

2018-11-0820 citations

10.1007/s00270-018-2110-1

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan

Hiroyoshi Yokoi, Takao Ohki, Kimihiko Kichikawa, Masato Nakamura, Kimihiro Komori et al. (10 authors)

JACC: Cardiovascular Interventions2016-02-0168 citations

10.1016/j.jcin.2015.09.035

Interventions

DEVICEZilver PTX Drug-Eluting Stent

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

* Symptomatic peripheral arterial disease (PAD) involving the above-the-knee femoropopliteal arteries

Design outcomes

Primary

Measure	Time frame
Occurrence of stent fracture	5 years
Rate of adverse events	5 years

Outcome results

None listed